Participated · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Series B · Jun 2026

Connie Health is an AI-native Medicare navigation platform that combines proprietary technology with a network of local trusted agents to help seniors find and enroll in appropriate Medicare coverage. The company powers agent workflows and consumer guidance with AI and intelligent automation and positions itself as a strategic partner to Accountable Care Organizations, health systems, and risk-bearing providers. Connie recently completed its 10th acquisition, integrating Clearlink's Medicare business, and announced a $40 million Series B, bringing total funding to date to $85 million. It plans to use capital to expand its agent network, pursue additional M&A, advance its AI-driven platform, and deepen integrations with value-based care partners. Connie is headquartered in Boston and emphasizes preserving local, human-centered support while scaling through technology.

Led · Equity · Mar 2026

Carefam is a New York City–based company building an AI-driven operational layer for the high-turnover healthcare labor market. Its core product is an always-on conversational AI engine that deploys specialized agents to autonomously handle recruiting and onboarding tasks, escalating only complex or sensitive decisions to human HR staff. The platform is already live in hundreds of acute care, long-term care, and home care organizations and has delivered 900% growth for the company over the past year. Recent funding will allow Carefam to scale the underlying AI infrastructure, deepen its suite of healthcare-focused agents, and broaden its footprint across additional care environments. Led by CEO and co-founder Matan Hoffmann and CTO Eyal Shulman, the team is focused on reducing administrative burden and improving hiring efficiency for healthcare providers. With fresh capital in hand, Carefam aims to cement its position as the de-facto conversational layer for healthcare staffing operations.

Led · Series B · Jul 2025

Restore Medical is a clinical-stage MedTech company based in Or Yehuda, Israel, developing novel minimally invasive transcatheter therapies for heart failure. Its core product is a transcatheter device intended to restore hemodynamic balance and improve clinical outcomes for patients with limited effective treatment options. The company reports promising long-term safety and efficacy from its European feasibility study, including meaningful improvements in ventricular reverse remodeling, hemodynamic performance, and patient functional capacity. Restore Medical received Breakthrough Device Designation from the U.S. Food and Drug Administration in 2024. The $23M Series B will fund completion of the ongoing European feasibility study and support the launch of a U.S.-based clinical study. The company was co-founded by Stephen Bellomo (CTO), Dr. Elchanan Bruckheimer (Medical Director), and Aaron Feldman, began operations within Peregrine Ventures' Incentive Incubator, and is led by CEO Gilad Marom.

Participated · Series A · May 2025

Somite.ai develops large-scale foundation models for human stem cells and a full-stack platform to accelerate discovery and optimization of cell therapies. The company’s proprietary capsule-based data generation platform produces differentiation data at approximately one‑thousandth the cost of traditional methods, enabling dense, causal datasets for training powerful predictive models. Somite combines low-cost data generation, large-scale model training, and model-driven discovery to compress development timelines for cell therapies. The company announced a collaboration with AMD Ventures to pair its platform with AMD Instinct GPUs, boosting compute for model training and exploring optimization of software tools for biological data. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone, the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. Somite is based in Boston, launched operations in January 2024, and has raised approximately $60M to date. Somite AI builds DeltaStem, a foundation-model platform and associated tools to design and optimize cell differentiation protocols for scalable human cell production. Its proprietary capsule technology generates cell state transition and signaling data at roughly 1,000x the efficiency of existing methods, which feeds DeltaStem. The company plans to use the platform to advance internal therapeutic programs including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders. Somite positions DeltaStem as a generalizable foundation model for developmental biology, aiming to deliver protocols with improved purity, scalability, and reliability. The company reported closing a Series A financing of more than $47 million to accelerate platform development and key programs. Founders and scientific leadership include Dr. Micha Breakstone and Dr. Jonathan Rosenfeld alongside noted academic co‑founders such as Olivier Pourquié, Allon Klein, Jay Shendure, and Cliff Tabin. Somite Therapeutics builds AI foundation models (AlphaStem) that generate large datasets to design and produce human tissues for cell-replacement therapies. The company focuses on developing scalable cell therapies for diseases such as diabetes, obesity, and muscular dystrophies, and its pipeline includes SMT-M01 for Duchenne muscular dystrophy and SMT-B01 for metabolic disorders. Somite plans to use generated data to iteratively improve its platform and expand therapy creation across broader indications. The team is led by founder and CEO Dr. Micha Breakstone and includes senior scientific and translational leaders and prominent academic co-founders. Financially, Somite completed a $4.8M extension of its pre-seed round, bringing total funds raised to over $10M. The new capital is earmarked to expedite data generation for AlphaStem, advance SMT-M01 toward the clinic, initiate the SMT-B01 program, and begin research with hypoimmune cell lines. Somite is a Boston, MA–based developer of AI for stem cell biology building foundation models to produce human tissue for cell therapies. Its proprietary AlphaStem AI platform generates massive datasets that improve the platform and enable therapy creation through rapid optimization cycles. The company focuses on producing cells derived from somites — including muscle, brown adipose, cartilage, bone, tendon, and dermis — to address diseases such as diabetes, obesity, and muscular dystrophies. Somite is also pioneering a computational digital twin of the embryo that draws on scRNA-Seq, scATAC-seq, and gene expression databases to mirror development and identify regulators of cell differentiation. The team combines AI and developmental biology expertise and includes CEO and co-founder Micha Breakstone alongside scientific co-founders such as Olivier Pourquie, Allon Klein, and Cliff Tabin. The company raised funding to continue development of AlphaStem and advance its platform.